These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 23055137

  • 1. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.
    Liu X, Mayes MD, Tan FK, Wu M, Reveille JD, Harper BE, Draeger HT, Gonzalez EB, Assassi S.
    Arthritis Rheum; 2013 Jan; 65(1):226-35. PubMed ID: 23055137
    [Abstract] [Full Text] [Related]

  • 2. Systemic sclerosis and lupus: points in an interferon-mediated continuum.
    Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, Chaussabel D, Oommen N, Fischbach M, Shah KR, Charles J, Pascual V, Reveille JD, Tan FK.
    Arthritis Rheum; 2010 Feb; 62(2):589-98. PubMed ID: 20112391
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.
    Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK, Impens AJ, Phillips K, Kahaleh B, Seibold JR, Koch AE.
    Arthritis Res Ther; 2011 Feb 08; 13(1):R18. PubMed ID: 21303517
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
    Brkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, van den Berg W, Dalm VA, Van Daele PL, Severino A, Maria NI, Guillen S, Dik WA, Beretta L, Versnel MA, Radstake T.
    Ann Rheum Dis; 2016 Aug 08; 75(8):1567-73. PubMed ID: 26371289
    [Abstract] [Full Text] [Related]

  • 9. Type I interferon system activation and association with disease manifestations in systemic sclerosis.
    Eloranta ML, Franck-Larsson K, Lövgren T, Kalamajski S, Rönnblom A, Rubin K, Alm GV, Rönnblom L.
    Ann Rheum Dis; 2010 Jul 08; 69(7):1396-402. PubMed ID: 20472592
    [Abstract] [Full Text] [Related]

  • 10. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients.
    Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C.
    Arthritis Res Ther; 2008 Jul 08; 10(5):R112. PubMed ID: 18793417
    [Abstract] [Full Text] [Related]

  • 11. The Th1 chemokine IP-10 in Systemic sclerosis.
    Corrado A.
    Clin Ter; 2014 Jul 08; 165(6):e436-41. PubMed ID: 25524202
    [Abstract] [Full Text] [Related]

  • 12. Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
    Steiman AJ, Gladman DD, Ibañez D, Noamani B, Landolt-Marticorena C, Urowitz MB, Wither JE.
    J Rheumatol; 2015 Dec 08; 42(12):2318-26. PubMed ID: 26568589
    [Abstract] [Full Text] [Related]

  • 13. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R, Mennella A, Palazzo R, Pietraforte I, Stefanantoni K, Iannace N, Butera A, Boirivant M, Pica R, Conrad C, Chizzolini C, Riccieri V, Frasca L.
    Int J Mol Sci; 2020 Jul 19; 21(14):. PubMed ID: 32707718
    [Abstract] [Full Text] [Related]

  • 14. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis.
    Assassi S, Wu M, Tan FK, Chang J, Graham TA, Furst DE, Khanna D, Charles J, Ferguson EC, Feghali-Bostwick C, Mayes MD.
    Arthritis Rheum; 2013 Nov 19; 65(11):2917-27. PubMed ID: 23897225
    [Abstract] [Full Text] [Related]

  • 15. Interferons dominate damage and activity in juvenile scleroderma.
    Kose H, Simsek A, Kizmaz MA, Bozkurt T, Ozturk F, Cekic S, Budak F, Sarıcaoglu H, Kilic SS.
    Mod Rheumatol; 2024 Oct 15; 34(6):1178-1184. PubMed ID: 38581664
    [Abstract] [Full Text] [Related]

  • 16. CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment.
    Bandinelli F, Del Rosso A, Gabrielli A, Giacomelli R, Bartoli F, Guiducci S, Matucci Cerinic M.
    Clin Exp Rheumatol; 2012 Oct 15; 30(2 Suppl 71):S44-9. PubMed ID: 22691208
    [Abstract] [Full Text] [Related]

  • 17. The role of type 1 interferon in systemic sclerosis.
    Wu M, Assassi S.
    Front Immunol; 2013 Sep 06; 4():266. PubMed ID: 24046769
    [Abstract] [Full Text] [Related]

  • 18. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.
    Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC.
    Arthritis Rheum; 2009 Oct 06; 60(10):3098-107. PubMed ID: 19790071
    [Abstract] [Full Text] [Related]

  • 19. Corticosteroid inhibits chemokines production in systemic sclerosis patients.
    Dantas AT, de Almeida AR, Sampaio MCPD, Cordeiro MF, da Rocha LF, de Oliveira PSS, Pereira MC, de Melo Rego MJB, Marques CDL, da Rocha Pitta I, Duarte ALBP, da Rocha Pitta MG.
    Steroids; 2017 Nov 06; 127():24-30. PubMed ID: 28866045
    [Abstract] [Full Text] [Related]

  • 20. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?
    Assassi S, Mayes MD.
    Curr Opin Rheumatol; 2013 Nov 06; 25(6):686-91. PubMed ID: 24061076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.